AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30150460
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 75 mg oseltamivir
Trial: 27793183
Drug: Sequential training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential training (SEQ)
Trial: 23616514
Drug: 1.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/d L-tryptophan
Trial: 23616514
Drug: 2.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/d L-tryptophan
Trial: 23616514
Drug: 3.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/d L-tryptophan
Trial: 23616514
Drug: 4.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g/d L-tryptophan
Trial: 23616514
Drug: 5.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g/d L-tryptophan
Trial: 10232640
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 g/d)
Trial: 22446172
Drug: Benfotiamine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (300 mg/day)
Trial: 20158623
Drug: Lifestyle factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle factors including drug usage patterns
Trial: 10422925
Drug: ANH (blinded,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANH (blinded, placebo injections)
Trial: 2104081
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate (TDB) maintenance therapy (120 mg Bi2O3, one swallow tablet nocte)
Trial: 692577
Drug: Solution or
RxNorm normalized name: Quindal Solution Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution or uncoated tablets
Trial: 692577
Drug: Sustained-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release formulations (3 of 6)
Trial: 692577
Drug: Sustained-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release formulations (3)
Trial: 692577
Drug: Uncoated tablets
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uncoated tablets
Trial: 25680689
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 3 grams daily for 3 weeks
Trial: 23755929
Drug: ER tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER tramadol 200 mg
Trial: 23755929
Drug: ER tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER tramadol 600 mg
Trial: 20934556
Drug: Edoxaban high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban high exposure (60 mg daily, adjusted for drug clearance)
Trial: 20934556
Drug: Edoxaban low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban low exposure (30 mg daily, adjusted for drug clearance)
Trial: 20934556
Drug: Warfarin titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin titrated to an international normalized ratio of 2.0 to 3.0
Trial: 1616967
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg twice daily for 7 days)
Trial: 30208601
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (Ca-antagonists)
Trial: 10373219
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACE-I)
Trial: 22828694
Drug: Thoracic intraarticular
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic intraarticular injections
Trial: 12011609
Drug: Fluoxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n = 13)
Trial: 10449104
Drug: Lenercept (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenercept (10, 50, or 100 mg IV every 4 weeks for up to 48 weeks)
Trial: 8960851
Drug: ramipril (2.5‐5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (2.5‐5.0 mg/day)
Trial: 24576401
Drug: Oral lipid-tolerance
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipid-tolerance test meal
Trial: 11960154
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg/day in 4 divided doses for first 4 days)
Trial: 9707026
Drug: Foscarnet 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet 90 mg/kg every 12 h for 15 days
Trial: 9707026
Drug: Ganciclovir 5
RxNorm normalized name: ganciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 5 mg/kg every 12 h for 15 days
Trial: 7631132
Drug: IVR 400
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVR 400 micrograms.kg-1 plus DEC 6 mg.kg-1
Trial: 7631132
Drug: DEC 6
RxNorm normalized name: Zodryl DEC 60 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 6 mg.kg-1
Trial: 7508065
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg daily
Trial: 31713733
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii Hook F (TwHF) 40-60 mg/day
Trial: 31713733
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYC) 100 mg/day
Trial: 29856176
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine with morphine plus nalbuphine (Group 2)
Trial: 29856176
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine with morphine (Group 1)
Trial: 24168638
Drug: Online personal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online personal activity monitor (Gruve Solution™)
Trial: 17709060
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (50 min, twice weekly for 4 weeks)
Trial: 17709060
Drug: Guided relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided relaxation (50 min, twice weekly for 4 weeks)
Trial: 9687407
Drug: Moxifloxacin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 50 mg
Trial: 9687407
Drug: Moxifloxacin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 100 mg
Trial: 9687407
Drug: Moxifloxacin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 200 mg
Trial: 9687407
Drug: Moxifloxacin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 600 mg
Trial: 2686488
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group K) - saline solution
Trial: 2686488
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg fentanyl (group 0,1F)
Trial: 2686488
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg fentanyl (group 0,2F)
Trial: 2686488
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg fentanyl (group 0,3F)
Trial: 2686488
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nifedipine (group 1,0N)
Trial: 2686488
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nifedipine + 0.1 mg fentanyl (group 0,5N + 0,1F)
Trial: 2686488
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nifedipine + 0.1 mg fentanyl (group 1,0N + 0,1F)
Trial: 326638
Drug: Metiamide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metiamide (400 mg)
Trial: 25464260
Drug: Short-term antihypertensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term antihypertensive treatment (median follow-up of 20 days)
Trial: 19126368
Drug: No epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No epidural steroid injection (Control)
Trial: 17955651
Drug: Electroacupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture plus acupoint-injection
Trial: 16020985
Drug: oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of trimetazidine, prednisolone, and vitamin B complex
Trial: 16020985
Drug: intravenous piracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous piracetam and prednisolone
Trial: 16020985
Drug: further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: further treatment with trimetazidine for a month
Trial: 16020985
Drug: timely initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timely initiation of therapy within the first week following acoustic trauma
Trial: 16020985
Drug: degree of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: degree of hearing improvement after medication
Trial: 11674925
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily for 4 weeks after a 2 week placebo period
Trial: 7889958
Drug: Cefprozil 20
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil 20 mg/kg once daily
Trial: 7889958
Drug: Cefprozil twice
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil twice daily
Trial: 7889958
Drug: Cefprozil once
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil once daily
Trial: 27323347
Drug: Zoledronate 4
RxNorm normalized name: zoledronic acid 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate 4 mg i.v. for 5 years, administered every 4 weeks for the first 6 months, every 3 months for the following 2 years, and every 6 months for the last 2.5 years.
Trial: 24121220
Drug: Bio-electro-magnetic-regulation treatment
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-electro-magnetic-regulation treatment
Trial: 24121220
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Bio-electro-magnetic-regulation treatment + Pentoxifylline infusions)
Trial: 18240145
Drug: Simultaneous castration
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous castration plus HTI-286 therapy
Trial: 16373903
Drug: Insulin analog
RxNorm normalized name: insulin analog, glargine 300 UNT Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin analog
Trial: 11221123
Drug: Home visits
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home visits to non-returners after treatment.
Trial: 8817142
Drug: Heparin-coated CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated CPB circuit with reduced systemic heparinization (ACT > 250 s) (n = 17)
Trial: 8817142
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with uncoated circuits and full heparin dose (ACT > 480 s) (n = 16)
Trial: 1306211
Drug: Pirenzepine (M1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (M1 muscarinic antagonist)
Trial: 1306211
Drug: Biperiden (M1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (M1 muscarinic antagonist)
Trial: 31661850
Drug: Treatment A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: 140 mg of ZynamiteÂ®, 140 mg of quercetin, 147.7 mg of maltodextrin, and 420 mg of sunflower lecithin
Trial: 31661850
Drug: Treatment B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: 140 mg of ZynamiteÂ®, 140 mg of quercetin, and 2126 mg of maltodextrin
Trial: 31661850
Drug: Treatment C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: 2548 mg of maltodextrin (placebo)
Trial: 26787023
Drug: Power whitening
RxNorm normalized name: NIACINAMIDE 2 g in 100 mL TOPICAL CREAM [DR.ALTHEA POWER WHITENING GLUTATHIONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power whitening gel (38% Hydrogen Peroxide)
Trial: 19733931
Drug: Customized chemotherapy
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized chemotherapy based on ERCC1 mRNA expression for patients with low levels of ERCC1 (docetaxel/cisplatin) and high levels of ERCC1 (docetaxel/gemcitabine)
Trial: 18585496
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin plus routine use of GP IIb/IIIa inhibitors
Trial: 14618108
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - micronized estradiol: 1 mg/day, progesterone: 0.25 mg/day
Trial: 11095120
Drug: Ketorolac-tobramycin combination
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ketorolac-tobramycin combination
Trial: 11095120
Drug: Fluorometholone-tobramycin combination
RxNorm normalized name: fluorometholone / tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorometholone-tobramycin combination
Trial: 1467386
Drug: m-chlorophenylpiperazine (mCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (mCPP) 0.35 mg/kg
Trial: 6369215
Drug: Balanced Salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced Salt Solution (BSS)
Trial: 30240280
Drug: 40% ASiR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% ASiR at normal dose (NI 10-40%)
Trial: 30240280
Drug: 40% ASiR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% ASiR at low dose (NI 20-40%)
Trial: 30240280
Drug: MBIR at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBIR at low dose (NI 20)
Trial: 27763682
Drug: Opicapone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone (5, 15, and 30 mg)
Trial: 27763682
Drug: Opicapone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone (5, 15, and 50 mg)
Trial: 25074885
Drug: Cinnamon ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon ointment, 2 mL every 12 h for 10 days
Trial: 25074885
Drug: Placebo ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment, 2 mL every 12 h for 10 days
Trial: 17517342
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum levels of apolipoprotein A-I (< 103 mg/dL)
Trial: 15133010
Drug: End-exercise pH
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-exercise pH across treatments
Trial: 11868527
Drug: Permanent magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permanent magnetic field (induction 60 mT) treatment
Trial: 1805138
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid combination
Trial: 28500678
Drug: BGG492 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 150 mg t.i.d.
Trial: 28500678
Drug: BGG492 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 100 mg t.i.d.
Trial: 28500678
Drug: BGG492 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 (both doses) during open-label extension study
Trial: 28500678
Drug: BGG492 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGG492 150 mg
Trial: 22010227
Drug: D2 agonist
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 agonist
Trial: 22010227
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor antagonist
Trial: 22010227
Drug: D1 receptor
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 receptor antagonist
Trial: 19895679
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment program (dose-matched)
Trial: 12827350
Drug: Alcohol (256
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (256 g per day)
Trial: 8450998
Drug: Low-dose apomorphine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose apomorphine (0.01 mg/kg) SC
Trial: 25333245
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate (PN) 450 mg per day
Trial: 8792921
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) with Parietaria extract
Trial: 1599300
Drug: Cisapride (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.8 mg/kg/day)
Trial: 30004916
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived mononuclear cells (BM-MNCs) injected intramuscularly at 40 locations of the calf muscle (500-700 mL harvested, 40 mL concentrated).
Trial: 26613203
Drug: PC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC treatment as usual (control group)
Trial: 25138064
Drug: Full-dose almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose almonds (50-100 g/d)
Trial: 25138064
Drug: Half-dose almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose almonds with half-dose muffins
Trial: 24925120
Drug: Full-dose muffins
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose muffins
Trial: 22762147
Drug: NOMAC/E2 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4‐day regimen (n= 56)
Trial: 22762147
Drug: LNG/EE (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE (150 μg/30 μg) in a 21/7‐day regimen (n= 54)
Trial: 20085939
Drug: sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib 400 mg twice daily
Trial: 24080250
Drug: Montelukast treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast treatment
Trial: 11870962
Drug: Preventive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive oral hygiene program (professional tooth cleaning, dental health information, and oral hygiene instruction) over a 6-month period
Trial: 11870962
Drug: Preventive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive oral hygiene program
Trial: 11686668
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol treatment for 24 hours
Trial: 11686668
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with transdermal oestradiol and medroxyprogesterone for 6 weeks
Trial: 7930300
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 25 micrograms twice daily
Trial: 8879892
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 micrograms twice daily
Trial: 8879892
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 micrograms twice daily
Trial: 16393726
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (all doses)
Trial: 12799091
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/d
Trial: 2439783
Drug: Bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 10 mg/d
Trial: 25012727
Drug: Subcutaneous pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous pasireotide (300, 600, or 900 μg)
Trial: 25012727
Drug: Intramuscular pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular pasireotide long-acting release (20, 40, or 60 mg)
Trial: 25012727
Drug: Subcutaneous pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous pasireotide